Sinopharm Group

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sinopharm Group
public
Traded as SEHK01099 (H share)
Industry Pharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
Founder China National Pharmaceutical Group
Headquarters Sinopharm Plaza, Shanghai, China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
Revenue Increase CN¥227.069 billion (2015)
Increase CN¥9.169 billion (2015)
Increase CN¥3.761 billion (2015)
Total assets Increase CN¥138.267 billion (2015)
Total equity Increase CN¥30.052 billion (2015)
Owner Sinopharm Industrial Investment (56.79%)
Parent Sinopharm Industrial Investment
Subsidiaries Sinopharm CNMC
Website www.sinopharmgroup.com.cn
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese 国药控股股份有限公司
Traditional Chinese 國藥控股股份有限公司
Literal meaning Sinopharm Holding Joint-Stock Limited Company
Sinopharm Group
Simplified Chinese 国药控股
Traditional Chinese 國藥控股
Literal meaning Sinopharm Holding
Second alternative Chinese name
Simplified Chinese 国控股份有限公司
Traditional Chinese 國控股份有限公司

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Sinopharm Group researches and develops, manufactures, distributes, and markets medicine and other healthcare products. Sinopharm Group manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[2] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[3]

See also[edit]

References[edit]

  1. ^ "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016. 
  2. ^ China's Sinopharm gets OK for $1 bln HK IPO
  3. ^ http://www.forbes.com/companies/sinopharm-group/

External links[edit]